Advertisement

PharmacoEconomics & Outcomes News

, Volume 842, Issue 1, pp 20–21 | Cite as

News from ISPOR: economics of emicizumab evaluated

Meeting report
  • 5 Downloads

This article highlights a selection of pharmacoeconomic studies on emicizumab (Hemlibra) in the treatment of haemophilia A that were presented as posters at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) which was held in November 2019 in Copenhagen, Denmark.

Emicizumab favourable in France

Emicizumab appears to be cost effective compared with standard treatment with bypassing agents (BPAs) in patients with haemophilia A in France, according to findings of a Roche-funded study.1

A Markov model populated with data from the HAVEN 1 trial was used to evaluate the cost effectiveness of prophylactic emicizumab compared with prophylactic BPAs (33%) or on-demand BPAs (67%) for the prevention of bleeding patients with haemophilia A, from a collective perspective in France over a 5-year time horizon.

In the base-case analysis, emicizumab prophylaxis was estimated to achieve a greater QALY gain than BPAs (3.3 vs 2.4) at a lower...

References

  1. 1.
    Godard C, et al. Cost-Effectiveness of Emicizumab Versus by-Passing Agents in Patients with Haemophilia a and Fviii Inhibitors in France. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PRO34, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/96183
  2. 2.
    Cortesi PA, et al. Emicizumab Prophylaxis in Haemophilia a Patients with Inhibitors- a Cost-Effectiveness and Budget Impact Analysis. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO28, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/97735
  3. 3.
    Soares V, et al. Cost-Effectiveness Analysis of Emicizumab for the Treatment of Patients with Haemophilia a with Inhibitors in Portugal. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY21, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3118/94847
  4. 4.
    Guler B, et al. Cost Minimization Analysis of Emicizumab in the Prophylaxis of Inhibitor-Negative Patients with Hemophilia a in Turkey. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO57, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/95540
  5. 5.
    Souza P, et al. Cost-Effectiveness Analysis of Emicizumab Versus Bypassing Agents in Patients with Hemophilia a with Inhibitors in the Brazilian Public Healthcare System Perspective. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO38, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/97736
  6. 6.
    Souza P, et al. Budget Impact Analysis of Emicizumab Prophylaxis for Haemophilia a Patients with Inhibitors in the Brazilian Public Healthcare System Perspective. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO36, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/98700
  7. 7.
    Lee H, et al. Emicizumab Prophylaxis is a Cost-Saving Option for Hemophilia a Patients with Inhibitors in Korea- a Cost-Effectiveness Analysis. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO46, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/94038

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations